2022
Increased Mortality in Patients Undergoing Inpatient Endoscopy During the Early COVID-19 Pandemic
Ilagan-Ying YC, Almeida MN, Kahler-Quesada A, Ying L, Hughes ML, Do A, Hung KW. Increased Mortality in Patients Undergoing Inpatient Endoscopy During the Early COVID-19 Pandemic. Digestive Diseases And Sciences 2022, 67: 5053-5062. PMID: 35182250, PMCID: PMC8857390, DOI: 10.1007/s10620-022-07414-x.Peer-Reviewed Original ResearchConceptsInpatient endoscopyCare centerEndoscopic proceduresIntensive care unit admissionAcademic tertiary care centerCare unit admissionProportion of patientsTertiary care centerCoronavirus disease 2019 (COVID-19) pandemicHigher mortality riskDisease 2019 pandemicEarly COVID-19 pandemicICU admissionUnit admissionPatient demographicsUrgent indicationsBlood transfusionFirst waveHigher proportionPatient reluctanceMale genderUrgent proceduresProcedural characteristicsHospital careMost healthcare systems
2023
Sa1547 IS TISSUE THE ISSUE? USE AND UTILITY OF LIVER BIOPSY IN A DEDICATED FATTY LIVER DISEASE CLINIC INCORPORATING METABOLIC HEALTH CARE
Ilagan-Ying Y, Tseng R, Valido K, Bollinger B, Kelly M, Do A. Sa1547 IS TISSUE THE ISSUE? USE AND UTILITY OF LIVER BIOPSY IN A DEDICATED FATTY LIVER DISEASE CLINIC INCORPORATING METABOLIC HEALTH CARE. Gastroenterology 2023, 164: s-1286-s-1287. DOI: 10.1016/s0016-5085(23)03992-6.Peer-Reviewed Original Research
2020
Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints
Do A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opinion On Drug Discovery 2020, 16: 125-134. PMID: 33086894, DOI: 10.1080/17460441.2020.1811674.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseaseFatty liver diseaseNonalcoholic steatohepatitisLiver diseaseHealthcare resource burdenNovel trial designsClinical trial researchSignificant healthcareCase definitionClinical trialsEfficacious treatmentNew therapiesEndpoint definitionsTrial designTreatment targetsMetabolic diseasesTrial researchClinical researchDrug development processQuality data reportingDrug approvalDiseaseResource burdenRegulatory pathwaysDrug development
2019
Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease
Do A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.Peer-Reviewed Original ResearchSuccessful weight lossFatty liver diseaseWeight lossLiver diseaseReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseWeight loss medicationsCurrent medical therapyPatient-centered approachMedical therapyPatient weightPatient evaluationMultisystemic complicationsEpidemic proportionsBehavioral change goalsNAFLDMedical approachObesityDiseaseMedicationsMultimodal approachFibrosisTreatmentSteatosisComplications